doi: 10.3389/fnut.2023.1157352 68 NacarelliTLauLFukumotoTZundellJFatkhutdinovNWuSet al
The single most important clinical datum: as of January 2025, no randomized controlled trial of BPC-157 in humans has been registered as completed with results posted on ClinicalTrials.gov for any indication, meaning every dose a patient takes is an unmonitored human experiment with no comparator arm and no systematic safety follow-up
Phase 1b (2021) Enebo and colleagues published a randomized, placebo-controlled, multiple-ascending-dose Phase 1b trial in The Lancet in 2021 [3]
The vial is convenient, well-packaged, and appears highly pure and reliable. Daniel K
DOI: Published: Publisher Name: Springer, New York, NY Print ISBN: 978-0-387-30342-0 Online ISBN: 978-0-387-30373-4 eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences
: BPC-157 may help stabilize nerve cells involved in tear production, a critical factor in managing dry eye